Taiwan-based CDMO Bora Pharma to pay up to $210M for Upsher-Smith to expand into the US
Taiwan-headquartered CDMO Bora Pharmaceuticals is buying generic manufacturer Upsher-Smith Laboratories for up to $210 million to expand operations into the US for the first time.
“This is a significant milestone for Bora Group, marking the most critical expansion of Bora’s presence in the US market,” Bora chairman and CEO Bobby Sheng said in a statement on Tuesday.
Bora will gain Upsher-Smith’s two manufacturing facilities in Plymouth and Maple Grove, MN, which can manufacture a range of product forms, including oral solids, topical powders and liquids. The sites also have packaging capabilities.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
